Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias or Solid Tumors
Status:
Recruiting
Trial end date:
2024-06-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and
efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias, lymphomas,
and solid tumors.